Article | Published:

The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores

Nature Genetics volume 41, pages 178186 (2009) | Download Citation

Abstract

For the past 25 years, it has been known that alterations in DNA methylation (DNAm) occur in cancer, including hypomethylation of oncogenes and hypermethylation of tumor suppressor genes. However, most studies of cancer methylation have assumed that functionally important DNAm will occur in promoters, and that most DNAm changes in cancer occur in CpG islands. Here we show that most methylation alterations in colon cancer occur not in promoters, and also not in CpG islands, but in sequences up to 2 kb distant, which we term 'CpG island shores'. CpG island shore methylation was strongly related to gene expression, and it was highly conserved in mouse, discriminating tissue types regardless of species of origin. There was a notable overlap (45–65%) of the locations of colon cancer–related methylation changes with those that distinguished normal tissues, with hypermethylation enriched closer to the associated CpG islands, and hypomethylation enriched further from the associated CpG island and resembling that of noncolon normal tissues. Thus, methylation changes in cancer are at sites that vary normally in tissue differentiation, consistent with the epigenetic progenitor model of cancer, which proposes that epigenetic alterations affecting tissue-specific differentiation are the predominant mechanism by which epigenetic changes cause cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Gene Expression Omnibus

References

  1. 1.

    & Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983).

  2. 2.

    & The history of cancer epigenetics. Nat. Rev. Cancer 4, 143–153 (2004).

  3. 3.

    & Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107–116 (2006).

  4. 4.

    et al. Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 18, 771–779 (2008).

  5. 5.

    & CpG islands in vertebrate genomes. J. Mol. Biol. 196, 261–282 (1987).

  6. 6.

    et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38, 1378–1385 (2006).

  7. 7.

    et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39, 457–466 (2007).

  8. 8.

    et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 6, e22 (2008).

  9. 9.

    et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 3, 2023–2036 (2007).

  10. 10.

    & CpG islands as genomic footprints of promoters that are associated with replication origins. Curr. Biol. 9, R661–R667 (1999).

  11. 11.

    DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400–5413 (2002).

  12. 12.

    et al. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc. Natl. Acad. Sci. USA 104, 10974–10979 (2007).

  13. 13.

    et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13, 5048–5055 (2007).

  14. 14.

    et al. Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J. Exp. Med. 205, 611–624 (2008).

  15. 15.

    et al. Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum. Mol. Genet. 17, 3864–3875 (2008).

  16. 16.

    et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 13, 806–815 (2007).

  17. 17.

    et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38, 1239–1241 (2006).

  18. 18.

    et al. Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res. 59, 5449–5451 (1999).

  19. 19.

    et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6, 361–371 (2004).

  20. 20.

    et al. Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc. Natl. Acad. Sci. USA 100, 15776–15781 (2003).

  21. 21.

    , , , & DBTSS: database of transcription start sites, progress report 2008. Nucleic Acids Res. 36, D97–D101 (2008).

  22. 22.

    et al. CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res. 35, 6798–6807 (2007).

  23. 23.

    , & The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21–33 (2006).

  24. 24.

    & Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Soc B (Methodol.) 57, 289–300 (1995).

  25. 25.

    The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Statist. 31, 2013–2035 (2003).

  26. 26.

    et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).

  27. 27.

    et al. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans. Med. Imaging 18, 32–42 (1999).

  28. 28.

    , , & Empirical Bayes analysis of a microarray experiment. J. Am. Stat. Assoc. 96, 1151–1160 (2001).

  29. 29.

    & DNA methylation analysis by pyrosequencing. Nat. Protocols 2, 2265–2275 (2007).

  30. 30.

    et al. An online database for brain disease research. BMC Genomics 7, 70 (2006).

  31. 31.

    , , & A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185–193 (2003).

  32. 32.

    & Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 25, 402–408 (2001).

  33. 33.

    et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).

  34. 34.

    & Using GOstats to test gene lists for GO term association. Bioinformatics 23, 257–258 (2007).

Download references

Acknowledgements

We thank B. Volgelstein (Johns Hopkins University School of Medicine) for providing colon tumors and matched normal mucosa samples. Postmortem brain, liver and spleen tissue was donated by The Stanley Medical Research Institute collection courtesy of M.B. Knable, E.F. Torrey and R.H. Yolken, whom we also thank for making available gene expression data for the brain and the liver tissue. We thank B. Carvalho for help with statistical software and C. Crainiceanu for advice with statistical methods. This work was supported by US National Institutes of Health grants P50HG003233 (A.P.F.), R37CA54358 (A.P.F.) and 5R01RR021967 (R.A.I.).

Author information

Author notes

    • Rafael A Irizarry
    • , Christine Ladd-Acosta
    •  & Andrew P Feinberg

    These authors contributed equally to this work.

Affiliations

  1. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.

    • Rafael A Irizarry
  2. Center for Epigenetics, Institute for Basic Biomedical Sciences, Baltimore, Maryland 21205, USA.

    • Rafael A Irizarry
    • , Christine Ladd-Acosta
    • , Bo Wen
    • , Carolina Montano
    • , Patrick Onyango
    • , Hengmi Cui
    • , Kevin Gabo
    • , Michael Rongione
    • , Hong Ji
    • , James B Potash
    • , Sarven Sabunciyan
    •  & Andrew P Feinberg
  3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

    • Christine Ladd-Acosta
    • , Bo Wen
    • , Carolina Montano
    • , Patrick Onyango
    • , Hengmi Cui
    • , Kevin Gabo
    • , Michael Rongione
    • , Hong Ji
    •  & Andrew P Feinberg
  4. Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.

    • Zhijin Wu
  5. Stanley Laboratory of Brain Research, Uniformed Services University of Health Sciences, Bethesda, Maryland 20892, USA.

    • Maree Webster
  6. Departments of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

    • James B Potash
  7. Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

    • Sarven Sabunciyan

Authors

  1. Search for Rafael A Irizarry in:

  2. Search for Christine Ladd-Acosta in:

  3. Search for Bo Wen in:

  4. Search for Zhijin Wu in:

  5. Search for Carolina Montano in:

  6. Search for Patrick Onyango in:

  7. Search for Hengmi Cui in:

  8. Search for Kevin Gabo in:

  9. Search for Michael Rongione in:

  10. Search for Maree Webster in:

  11. Search for Hong Ji in:

  12. Search for James B Potash in:

  13. Search for Sarven Sabunciyan in:

  14. Search for Andrew P Feinberg in:

Contributions

R.A.I. and A.P.F. designed the study and interpreted the results; R.A.I. designed new CHARM arrays and statistical methods with Z.W.; C.L.-A. performed bisulfite pyrosequencing, real-time quantitative PCR and sample preparation with C.M., K.G., M.R. and H.J.; B.W. and S.S. performed CHARM assays with sample preparation from M.W. and advice from J.B.P.; P.O. and H.C. performed functional assays; A.P.F. supervised the laboratory experiments and wrote the paper with R.A.I. and C.L.-A.

Corresponding authors

Correspondence to Rafael A Irizarry or Andrew P Feinberg.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–5, Supplementary Tables 1–7 and Supplementary Methods

Excel files

  1. 1.

    Supplementary Data 1

    Excel file of T-DMRs

  2. 2.

    Supplementary Data 2

    Excel file of C-DMRs

  3. 3.

    Supplementary Data 3

    Gene expression data from 5-aza-2′ deoxycytidine/DKO experiments and gene expression data for genes associated with T-DMRs

  4. 4.

    Supplementary Data 4

    Excel file of C-DMRs that are also T-DMRs; and C-DMRs that distinguish all the tumors from normal

  5. 5.

    Supplementary Data 5

    Mus musculus T-DMRs

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.298

Further reading